A Director at Concert Pharma is Exercising Options

By Carrie Williams

Today, a Director at Concert Pharma, Ronald Barrett, exercised options of Concert Pharma for $349.7K.

Following Ronald Barrett’s last CNCE Sell transaction on November 10, 2015, the stock climbed by 0.7%.

Based on Concert Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $144 million and quarterly net profit of $127 million. In comparison, last year the company earned revenue of $26K and had a GAAP net loss of $11.36 million. The company has a one-year high of $25.41 and a one-year low of $7.11. CNCE’s market cap is $534M and the company has a P/E ratio of 6.31.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $24.67, reflecting a -4.1% downside.

The insider sentiment on Concert Pharma has been neutral according to 14 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs for renal disease, CNS disorders, inflammation and hematologic disorders. It also creates novel medicines that address commercially important needs by applying its deuterated chemical entity platform to compounds with well-characterized pharmacological activity. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.